The Utility of α-Synuclein as Biofluid Marker in Neurodegenerative Diseases: a Systematic Review of The Literature

Anja Hviid Simonsen; Bea Kuiperij; Omar Mukhtar Ali El-Agnaf; Sebastian Engelborghs; Sanna-Kaisa Herukka; Lucilla Parnetti; Irena Rektorová; Eugeen Vanmechelen; Elisabeth Kapaki; Marcel Verbeek; Brit Mollenhauer

doi:10.2217/bmm.14.105

journal article Aug 28, 2015

The Utility of α-Synuclein as Biofluid Marker in Neurodegenerative Diseases: a Systematic Review of The Literature

Anja Hviid Simonsen Bea Kuiperij Omar Mukhtar Ali El-Agnaf Sebastian Engelborghs Sanna-Kaisa Herukka Lucilla Parnetti

Irena Rektorová

Eugeen Vanmechelen

Elisabeth Kapaki Marcel Verbeek Brit Mollenhauer

Biomarkers in Medicine Vol. 10 No. 1 pp. 19-34 · Informa UK Limited

View at Publisher Save 10.2217/bmm.14.105

Topics

No keywords indexed for this article. Browse by subject →

References

94

[1]

10.1007/s00401-010-0665-2

[2]

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

A J Hughes, S E Daniel, L Kilford et al.

Journal of Neurology, Neurosurgery &amp; Psych... 10.1136/jnnp.55.3.181

[3]

10.1096/fj.03-0098fje

[4]

10.2217/bmm.10.90

[5]

10.1006/bbrc.1994.2816

[6]

10.1016/0888-7543(95)80208-4

[7]

10.1016/j.expneurol.2008.06.004

[8]

10.1016/j.bbrc.2006.08.024

[9]

10.1016/j.jneumeth.2007.09.021

[10]

10.1212/wnl.0b013e3181fd613b

[11]

10.1002/mds.23670

[12]

10.3389/fnagi.2014.00053

[13]

10.3233/jad-2010-100186

[14]

10.1016/j.neurobiolaging.2010.12.001

[15]

10.3988/jcn.2011.7.4.215

[16]

Elevated levels of cerebrospinal fluid Î±-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers

Jan O. Aasly, Krisztina K. Johansen, Gunnar BrÃ¸nstad et al.

Frontiers in Aging Neuroscience 10.3389/fnagi.2014.00248

[17]

10.1002/jnr.22417

[18]

10.1002/mds.22928

[19]

10.1097/wad.0b013e31823899cc

[20]

10.1016/j.neurobiolaging.2008.06.010

[21]

10.1159/000321342

[22]

10.1159/000329763

[23]

10.1371/journal.pone.0053250

[24]

10.1111/j.1471-4159.2012.07749.x

[25]

10.1074/jbc.m112.379792

[26]

10.1371/journal.pone.0022225

[27]

10.1016/j.jneumeth.2011.05.020

[28]

10.1007/s00401-012-0964-x

[29]

10.1016/j.neulet.2008.11.015

[30]

Kruse N , VanmechelenE, SchlossmacherMGet al. Sensitive multiplex quantification of alpha-Synuclein, DJ-1, beta-Amyloid 1–42 and Tau protein in human biological fluids based on chemiluminescence detection. Neurodegener. Dis.11(Suppl. 1) (2013).

[31]

10.1016/j.ymeth.2012.03.016

[32]

10.1136/jnnp.2009.197483

[33]

10.1093/brain/awq008

[34]

10.1016/j.neulet.2012.11.004

[35]

10.1016/s1474-4422(11)70014-x

[36]

10.3233/jad-130458

[37]

10.1007/s00401-013-1148-z

[38]

10.1001/archneurol.2012.1654

[39]

Slaets S , VanmechelenE, Le BastardNet al. Increased CSF alpha-synuclein levels in Alzheimer’s disease: correlation with tau levels. Alzheimers Dement.10(5, Suppl.), S290–S298 (2014).

[40]

Kang JH , IrwinDJ, Chen-PlotkinASet al. Association of cerebrospinal fluid beta-amyloid 1–42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA neurol.70(10), 1277–1287 (2013).

[41]

10.1016/j.parkreldis.2014.01.011

[42]

10.1006/jsbi.2000.4262

[43]

10.1016/s0896-6273(03)00024-2

[44]

Paleologou KE , KraghCL, MannDMet al. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain132(Pt 4), 1093–1101 (2009). 10.1093/brain/awn349

[45]

10.1096/fj.05-5422com

[46]

10.1096/fj.03-1449com

[47]

10.1038/ncb748

[48]

10.1074/jbc.m600933200

[49]

10.1016/j.ajpath.2012.11.018

[50]

10.1016/s1474-4422(03)00481-2

Showing 50 of 94 references

Cited By

85

Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease?

Kurt A. Jellinger, Amos D. Korczyn · 2018

BMC Medicine

Metrics

85

Citations

94

References

Details

Published: Aug 28, 2015
Vol/Issue: 10(1)
Pages: 19-34

Authors

A

Anja Hviid Simonsen

Memory Disorders Research Group,

B

Bea Kuiperij

Department of Neurology,

O

Omar Mukhtar Ali El-Agnaf

College of Science and Engineering,

S

Sebastian Engelborghs

Reference Center for Biological Markers of Dementia (BIODEM),

S

Sanna-Kaisa Herukka

Institute of Clinical Medicine–Neurology University of Eastern Finland School of Medicine,

L

Lucilla Parnetti

Centro Disturbi della Memoria- Unità Valutativa Alzheimer,

I

Irena Rektorová

Applied Neuroscience Research Group,

ADx NeuroSciences,

National & Kapodistrian University of Athens,

M

Marcel Verbeek

Department of Neurology,

B

Brit Mollenhauer

Paracelsus-Elena-Klinik,

Funding

European Regional Development Fund

NSRF

Denmark

Finland (Academy of Finland

Germany

Italy

The Netherlands:

University of Antwerp Research Fund and the Alzheimer Research Foundation

Greek national funds through the Operational Program ‘Competitiveness and Entrepreneurship’ of the NSRF (National Strategic Reference Framework);

Reek national funds through the Operational Program ‘Competitiveness and Entrepreneurship’

BMBF, EU, Deutsche Parkinson Vereinigung, Michael J. Fox Foundation for Parkinson’s Research

, Stifterverband für die deutsche Wissenschaft, and has scientific collaborations with Roche, Ely Lilly, BioLegend and Biogen Idec

Cite This Article

Anja Hviid Simonsen, Bea Kuiperij, Omar Mukhtar Ali El-Agnaf, et al. (2015). The Utility of α-Synuclein as Biofluid Marker in Neurodegenerative Diseases: a Systematic Review of The Literature. Biomarkers in Medicine, 10(1), 19-34. https://doi.org/10.2217/bmm.14.105

The Utility of α-Synuclein as Biofluid Marker in Neurodegenerative Diseases: a Systematic Review of The Literature

You May Also Like